Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock Position Lowered by Highland Capital Management LLC

Highland Capital Management LLC lessened its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 32,470 shares of the specialty pharmaceutical company’s stock after selling 390 shares during the quarter. Highland Capital Management LLC owned approximately 0.05% of Jazz Pharmaceuticals worth $3,910,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its stake in Jazz Pharmaceuticals by 0.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company’s stock valued at $1,937,000 after buying an additional 99 shares during the period. Waterfront Wealth Inc. increased its stake in Jazz Pharmaceuticals by 1.2% in the 4th quarter. Waterfront Wealth Inc. now owns 8,633 shares of the specialty pharmaceutical company’s stock valued at $1,062,000 after buying an additional 103 shares during the period. Prime Capital Investment Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 4.3% during the 4th quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company’s stock worth $325,000 after purchasing an additional 108 shares during the last quarter. Ontario Teachers Pension Plan Board increased its stake in shares of Jazz Pharmaceuticals by 0.4% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 29,749 shares of the specialty pharmaceutical company’s stock worth $3,659,000 after purchasing an additional 108 shares during the last quarter. Finally, Pinnacle Associates Ltd. increased its stake in shares of Jazz Pharmaceuticals by 1.1% during the 1st quarter. Pinnacle Associates Ltd. now owns 10,371 shares of the specialty pharmaceutical company’s stock worth $1,249,000 after purchasing an additional 110 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the transaction, the executive vice president now directly owns 36,629 shares in the company, valued at $4,016,369.85. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Down 0.4 %

JAZZ traded down $0.45 during trading on Friday, reaching $105.59. The company had a trading volume of 451,000 shares, compared to its average volume of 656,405. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.90. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $146.70. The business’s fifty day moving average price is $107.73 and its 200 day moving average price is $115.45. The company has a market cap of $6.66 billion, a P/E ratio of 21.77, a PEG ratio of 1.62 and a beta of 0.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The company had revenue of $901.98 million during the quarter, compared to the consensus estimate of $938.99 million. Equities analysts anticipate that Jazz Pharmaceuticals plc will post 15.35 EPS for the current year.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several recent analyst reports. StockNews.com downgraded shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, July 5th. Barclays decreased their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Friday, May 3rd. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, June 5th. They set a “buy” rating and a $169.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, May 3rd. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $185.86.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.